Clinical trials: Mesotheliomas Pleural
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma.
- Conditions
- Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma
- Trial name
- NCT02408016
- Testing
- Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Lung Cancer, Non-small Cell, Small Cell Lung Cancer
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
- Conditions
- Lung Cancer, Non-small Cell, Small Cell Lung Cancer, Pleural Mesothelioma
- Trial name
- NCT05628376
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- University College, London
Pleural Mesothelioma, Asbestos Exposure
Mesothelioma Early Detection by VOCs
This is a two phase study, The first phase (phase 1) will identify potential biomarkers among asbestos exposed individuals with pleural mesothelioma.
- Conditions
- Pleural Mesothelioma, Asbestos Exposure, Pleural Plaque
- Trial name
- MED-VOC (NCT04106973)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Henry Ford Health System
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma, Advanced
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced…
- Trial name
- NCT06031636
- Testing
- Oncolytic Adenovirus H101, Programmed death receptor-1 inhibitor
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Second Hospital
Malignant Pleural Mesothelioma
Trimodality Therapy for Malignant Pleural Mesothelioma
The role of surgical resection in the management of Malignant Pleural Mesothelioma (MPM) is still controversial. The selection criterion to perform either Extrapleural Pneumonectomy (EPP) or Pleurectomy/Decortication (P/D) is…
- Trial name
- NCT01343264
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- HSK Wiesbaden
Malignant Pleural Mesothelioma
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
- Trial name
- NCT04162015
- Testing
- Nivolumab, Pemetrexed, Cisplatin or Carboplatin
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Mesothelioma
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
- Trial name
- NCT03683680
- Testing
- MPT Test, CLDN15/VIM Test
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Dana-Farber Cancer Institute
Mesothelioma, Mesotheliomas Pleural
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
Pleural and peritoneal mesotheliomas (PPM) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options and a dismal prognosis.
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung
- Trial name
- Imaging-Meso (NCT06581549)
- Testing
- Translation analysis
- Where
- 10 sites in Italy
- Volunteers
- 125 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Pleural Mesothelioma, Non-small Cell Lung Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: To confirm the dose and to assess the safety profile of SAR444245 when…
- Trial name
- NCT04914897
- Testing
- THOR-707, Pembrolizumab
- Where
- 35 sites in United States, Argentina and 9 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Mesothelioma, Malignant Mesothelioma (MM)
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
Background: Mesothelioma is a rare cancer typically caused by exposure to asbestos and related fibers. Most people with mesothelioma survive less than 5 years after diagnosis.
- Conditions
- Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma
- Trial name
- NCT06654050
- Testing
- alrizomadlin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for…
- Trial name
- NCT02372227
- Testing
- VS-5584 and VS-6063
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Verastem, Inc.
Malignant Pleural Mesothelioma
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
Mesothelioma is a relatively rare cancer which is becoming more common. It can affect one of two areas; the pleura (the lining of the lung) or the peritoneum (the lining of the abdomen).
- Trial name
- MESO-02 (NCT01353482)
- Testing
- Cisplatin, Pemetrexed, Vorinostat
- Sponsor
- University College, London
Lung Cancer, Gastro-Intestinal Cancer
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
This study evaluates physical performance in cancer outpatients during a multimodal therapy. Half of the patients will receive physical exercise und nutrition program in combination with a specially formulated whey protein…
- Conditions
- Lung Cancer, Gastro-Intestinal Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02585362
- Testing
- physical exercise, nutrition counseling, whey protein supplement
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- Kantonsspital Winterthur KSW
Mesothelioma, Malignant, Mesothelioma, Malignant Pleural
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma.
- Conditions
- Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
- Trial name
- NCT05188859
- Testing
- Sintilimab+Anlotinib+Pemetrexed+Cisplatin
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Malignant Pleural Mesothelioma
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
This is a prospective study evaluating the effect of expression of CD74 and VEGF on outcome of treatment in patients with malignant pleural mesothelioma receiving Pemetrexed/Platinum protocol.
- Trial name
- NCT02761863
- Testing
- CD 74, VEGF detection
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Meso-Immune is a retrospective study to assess the efficacy and safety of the combination of Nivolumab and Ipilimumab used in first-line treatment of adult patients with unresectable Malignant Pleural Mesothelioma (MPM).
- Trial name
- MESO-IMMUNE (NCT05308966)
- Testing
- Data collection
- Where
- 63 sites in France
- Volunteers
- 204 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Malignant Mesothelioma
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00017186
- Testing
- epirubicin hydrochloride, gemcitabine hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology